SCHEMBL209844

SCHEMBL209844

c1cc(N2CCCCC2)ncn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORD Q00796 1/20 0.54
CHKA P35790 1/20 0.48
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
ALOX12 P18054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 1/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CNR2 P34972 4/20 0.44
GPR119 Q8TDV5 1/20 0.43
GSK3B P49841 1/20 0.43
DRD4 P21917 1/20 0.43
CXCR4 P61073 1/20 0.42
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
CDC42BPB Q9Y5S2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209842 1.00 SORD (0.54) SORDCHKAMAPTALDH1A1LMNA
SCHEMBL29611181 1.00 SORD (0.54) SORDCHKAMAPTALDH1A1LMNA
SCHEMBL4453478 0.98 SORD (0.56) SORDCHKAMAPTALDH1A1LMNA
SCHEMBL30775404 0.98 SORD (0.56) SORDCHKAMAPTALDH1A1LMNA
SCHEMBL9767811 0.89
Imidazole SCHEMBL19693057 0.83 SORD (0.48) SORDCHKAMAPTALDH1A1LMNA
SCHEMBL24742884 0.82 SORD (0.50) SORDALDH1A1TSHRGSK3BROCK2
SCHEMBL2224541 0.82 SORD (0.53) SORDGPR119DRD4ROCK1AKT1
SCHEMBL2103794 0.82 SORD (0.53) SORDGPR119DRD4ROCK1AKT1
SCHEMBL9558132 0.80 SORD (0.55) SORDALDH1A1TSHRGPR119GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4960888-A Preparation of 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine compounds RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1990-10-02 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
US-20220010323-A1 METHOD TO OBTAIN LOW TRITERPENE/TRITERPENOID-CONTAINING NATURAL RUBBER LATEX FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2022-01-13 US disclosed
EP-3877518-A1 METHOD TO OBTAIN LOW TRITERPENE/TRITERPENOID-CONTAINING NATURAL RUBBER LATEX Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2021-09-15 EP disclosed
CN-112955545-A Method for obtaining natural rubber latex with low triterpene/triterpenoid content 弗劳恩霍夫应用研究促进协会 2021-06-11 CN disclosed
EP-3650542-A1 METHOD TO OBTAIN LOW TRITERPENE/TRITERPENOID-CONTAINING NATURAL RUBBER LATEX Fraunhofer Gesellschaft zur Förderung der Angewand (DE) 2020-05-13 EP disclosed
CN-109731001-A The newly new application of fine jade oligosaccharides and the composition containing new fine jade oligosaccharides 蓝脑科技(厦门)有限公司 2019-05-10 CN disclosed
CN-109053742-A New tricyclic compound ABBVIE 公司 2018-12-21 CN disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
EP-1049473-A1 PYRIMIDIN 3-OXIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PATHOLOGIES OF THE SKELETAL MUSCLE, IN PARTICULAR FOR THE TREATMENT OF THE HYPOKALEMIC PARALYSIS Paolini, Moreno (IT) 2000-11-08 EP disclosed
WO-1999036072-A1 PYRIMIDIN 3-OXIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PATHOLOGIES OF THE SKELETAL MUSCLE, IN PARTICULAR FOR THE TREATMENT OF THE HYPOKALEMIC PARALYSIS PAOLINI MORENO (IT) 1999-07-22 WO disclosed
EP-0640599-B1 4-Aminopyrimidine derivatives ONO PHARMACEUTICAL CO (JP) 1998-03-04 EP disclosed
US-5525604-A USED IN PREVENTION OR TREATMENT OF THROMBOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASES, GASTRIC ULCER OR HYPERTENSION ONO PHARMACEUTICAL CO., LTD. (JP) 1996-06-11 US disclosed
CN-1109055-A 4-aminopyrimidine derivatives ONO PHARMACEUTICAL CO (JP) 1995-09-27 CN disclosed
EP-0640599-A1 4-Aminopyrimidine derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-03-01 EP disclosed
CN-86102398-A The preparation method of substituted benzimidazole derivative 1986-11-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020645-A1 Diamine derivatives C9, C1S, C1R SORD 2798/4885CHKA 4617/4885MAPT 4271/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR SORD 3130/4885CHKA 3963/4885MAPT 2789/4885
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN SORD 4280/4885CHKA 555/4885MAPT 673/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR SORD 3130/4885CHKA 3963/4885MAPT 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.